InflaRx Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 65

Employees

  • Stock Symbol
  • IFRX

Stock Symbol

  • Share Price
  • $1.11
  • (As of Wednesday Closing)

InflaRx General Information

Description

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Contact Information

Website
www.inflarx.de
Formerly Known As
Fireman B.V
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Winzerlaer Street 2
  • 07745 Jena
  • Germany
+49 03641
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • Winzerlaer Street 2
  • 07745 Jena
  • Germany
+49 03641

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

InflaRx Stock Performance

As of 18-Nov-2026, InflaRx’s stock price is $1.11. Its current market cap is $164M with 147M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.11 $1.15 $0.80 - $2.95 $164M 147M 867K -$0.37

InflaRx Financials Summary

As of 30-Sep-2026, InflaRx has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 85,210 17,191 81,788 (24,258)
Revenue 0 33 179 68
EBITDA (36,780) (53,026) (52,753) (49,634)
Net Income (34,070) (51,475) (49,846) (46,169)
Total Assets 182,938 64,858 79,103 132,879
Total Debt 919 1,055 838 1,238
Public Fundamental Data provided by Morningstar, Inc. disclaimer

InflaRx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore InflaRx‘s full profile, request access.

Request a free trial

InflaRx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize poten
Drug Discovery
Jena, Germany
65 As of 2025

Houston, TX
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InflaRx Competitors (49)

One of InflaRx’s 49 competitors is OncoResponse, a Venture Capital-Backed company based in Houston, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
OncoResponse Venture Capital-Backed Houston, TX
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
XBiotech Corporation Austin, TX
Vir Biotechnology Formerly VC-backed San Francisco, CA
You’re viewing 5 of 49 competitors. Get the full list »

InflaRx Patents

InflaRx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2026529093-A Condensed piperidinyl bicyclic compounds and related compounds for use in the treatment of diseases Pending 16-Aug-2023
AU-2024324780-A1 Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases Pending 16-Aug-2023
EP-4761731-A1 Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases Pending 16-Aug-2023
WO-2025037010-A1 Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases Inactive 16-Aug-2023
US-12180274-B2 Treatment of pneumonia and ards with inhibitors of c5a and il-6 activity Active 26-May-2023 C07K16/248
To view InflaRx’s complete patent history, request access »

InflaRx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InflaRx ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view InflaRx’s complete esg history, request access »

InflaRx FAQs

  • When was InflaRx founded?

    InflaRx was founded in 2007.

  • Where is InflaRx headquartered?

    InflaRx is headquartered in Jena, Germany.

  • What is the size of InflaRx?

    InflaRx has 65 total employees.

  • What industry is InflaRx in?

    InflaRx’s primary industry is Drug Discovery.

  • Is InflaRx a private or public company?

    InflaRx is a Public company.

  • What is InflaRx’s stock symbol?

    The ticker symbol for InflaRx is IFRX.

  • What is the current stock price of InflaRx?

    As of 18-Nov-2026 the stock price of InflaRx is $1.11.

  • What is the current market cap of InflaRx?

    The current market capitalization of InflaRx is $164M.

  • Who are InflaRx’s competitors?

    OncoResponse, CytomX Therapeutics, Kite Pharma, XBiotech, and Vir Biotechnology are some of the 49 competitors of InflaRx.

  • What is InflaRx’s annual earnings per share (EPS)?

    InflaRx’s EPS for 12 months was -$0.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process